Ketogenic Diet Added To Chemotherapy In Metastatic Pancreatic Cancer

A recent study reports outcomes when a medically supervised ketogenic diet was added to gemcitabine, nab-paclitaxel, and cisplatin in patients with treatment-naive metastatic pancreatic ductal adenocarcinoma. Investigators used a randomized phase II screening design, comparing the regimen plus diet support with the same chemotherapy given alongside a usual diet. The trial focused on untreated metastatic disease and followed both diet implementation and clinical outcome measures during treatment.

Participants were assigned 1:1 to the ketogenic program or to a usual diet, with both groups receiving the same chemotherapy schedule. Authors described the diet arm as guided by a remote health care team and by daily beta-hydroxybutyrate monitoring aimed at 0.5 to 3.0 mM. Dietary counseling was paired with serial ketone assessment during protocol therapy, outlining the intervention’s supervision and monitoring framework.

In the evaluable ketogenic-diet group, 15 of 16 patients reached nutritional ketosis during trial participation. Investigators also reported a median of 39.4% of days spent in ketosis within that study arm. These feasibility measures addressed whether monitored diet support could produce and sustain the intended metabolic state over time during therapy.

For efficacy, the study reported a median progression-free survival of 8.5 months in the ketogenic-diet arm versus 6.2 months in the usual-diet arm. The reported hazard ratio for progression-free survival was 0.53 (95% CI, 0.21–1.37), with a one-sided P value of .096. Median overall survival was 13.7 months in the ketogenic-diet group versus 10.2 months in the usual-diet group. The reported hazard ratio for overall survival was 0.58 (95% CI, 0.25–1.37), with a one-sided P value of .107. Across both time-to-event endpoints, the abstract described numerically longer median survival values in the diet arm as a screening signal.

On tolerability, all diet-related adverse events were grade 1 to 2, and no significant difference was reported in grade 3 or higher chemotherapy-related adverse events between arms. Investigators also reported no decline in quality of life among patients receiving the ketogenic diet. In correlative analyses, the authors observed enrichment of beneficial microbiome taxa and described microbiome changes as an exploratory endpoint.

Key Takeaways

• A randomized phase II screening study compared chemotherapy with or without a medically supervised ketogenic diet in treatment-naive metastatic pancreatic ductal adenocarcinoma.
• Most evaluable patients assigned to the diet arm achieved nutritional ketosis.
• Reported findings included numerically longer survival medians, grade 1 to 2 diet-related adverse events, no quality-of-life decline, and an exploratory microbiome signal.